Table 1 Clinicopathologic characteristics of patients with resectable recurrent esophageal cancer
From: Post-recurrence survival analysis in patients with oligo-recurrence after curative esophagectomy
Operation group (N = 30) | Non-operation group (N = 33) | p value | |
|---|---|---|---|
Age, years, median (IQR) | 52 (47–59) | 60 (53–68) | 0.003 |
Sex (%) | 0.945 | ||
Male | 29 (96.7%) | 32 (97.0%) | |
Female | 1 (3.3%) | 1 (3.0%) | |
Tumor location (%) | 0.285 | ||
Upper/middle third | 18 (60.0%) | 24 (72.7%) | |
Lower third/GE junction | 12 (40.0%) | 9 (27.3%) | |
Histologic cell type (%) | 0.612 | ||
Squamous cell carcinoma | 29 (96.7%) | 31 (93.9%) | |
Adenocarcinoma or other | 1 (3.3%) | 2 (6.1%) | |
Tumor length, cm, median (IQR) | 3.5 (2.3–5.0) | 3 (2.0–5.0) | 0.560 |
Pathologic T stage (%) | 0.222 | ||
ypT0 | 8 (26.7%) | 4 (12.1%) | |
(y)pT1 | 6 (20.0%) | 6 (18.2%) | |
(y)pT2 | 6 (20.0%) | 4 (12.1%) | |
(y)pT3 | 10 (33.3%) | 19 (57.6%) | |
Pathologic N stage (%) | 0.904 | ||
N0 | 15 (50.0%) | 17 (51.5%) | |
N1/N2/N3 | 15 (50.0%) | 16 (48.5%) | |
Differentiation (%) | 0.334 | ||
Grade X (cannot be assessed) | 8 (26.7%) | 5 (15.2%) | |
Well/moderately | 18 (60.0%) | 21 (63.6%) | |
Poorly | 4 (13.3%) | 7 (21.2%) | |
Lymphovascular invasion (%) | 0.961 | ||
Negative | 18 (60.0%) | 20 (60.6%) | |
Positive | 12 (40.0%) | 13 (39.4%) | |
Perineural invasion (%) | 0.540 | ||
Negative | 27 (90.0%) | 28 (84.8%) | |
Positive | 3 (10.0%) | 5 (15.2%) | |
Circumferential margin (%) | 0.224 | ||
Uninvolved | 27 (90.0%) | 26 (78.8%) | |
Involved/close | 3 (10.0%) | 7 (21.2%) | |
Treatment modality (%) | 0.108 | ||
Neoadjuvant treatments + surgery | 13 (43.3%) | 8 (24.2%) | |
Upfront surgery | 17 (56.7%) | 25 (75.8%) | |
Initial surgery method | 0.476 | ||
Mckeown esophagectomy | 29 (96.7%) | 33 (100.0%) | |
Ivor lewis approach | 1 (3.3%) | 0 | |
Tumor regression grade (%) | 0.948 | ||
0 | 8 (26.7%) | 4 (12.1%) | |
1 | 3 (10.0%) | 2 (6.1%) | |
2 | 1 (3.3%) | 1 (3.0%) | |
3 | 1 (3.3%) | 1 (3.0%) | |
Disease free interval (%) | |||
≤ 12 months | 13 (43.3%) | 18 (54.5%) | 0.374 |
> 12 months | 17 (56.7%) | 15 (45.5%) | |
Charlson Comorbidity Index (%) | 0.547 | ||
0 | 15 (50.0%) | 19 (57.6%) | |
≥ 1 | 15 (50.0%) | 14 (42.4%) | |
Performance status (%) | 0.409 | ||
0 | 22 (73.3%) | 21 (63.6%) | |
1 | 8 (26.7%) | 12 (36.4%) | |
Recurrence pattern (%) | 0.003 | ||
Locoregional recurrence | 7 (23.3%) | 20 (60.6%) | |
Distant metastasis | 23 (76.7%) | 13 (39.4%) | |
Total recurrence (%) | 0.002 | ||
Anastomosis | 1 (3.3%) | 4 (12.1%) | |
Cervical lymph node | 5 (16.7%) | 6 (18.2%) | |
Mediastinal lymph node | 1 (3.3%) | 10 (30.3%) | |
Lung | 17 (56.7%) | 4 (12.1%) | |
Chest wall/ pleura seeding | 2 (6.7%) | 3 (9.1%) | |
Liver | 1 (3.3%) | 3 (9.1%) | |
Brain | 3 (10.0%) | 0 | |
Bone | 0 | 2 (6.1%) | |
Spleen | 0 | 1 (3.0%) | |